Valerio Therapeutics (XPAR:ALVIO) Accounts Payable: €2.28 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALVIO Valerio Therapeutics XPAR:ALVIO
28 GF Score
Price €0.61
GF Value €0.07
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Valerio Therapeutics Accounts Payable?

Valerio Therapeutics XPAR:ALVIO +2.18% 28 Accounts Payable is €2.28 Mil as of Dec. 2025. GuruFocus rates XPAR:ALVIO with a GF Score™ of 28/100 and a GF Value™ of €0.07 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Valerio Therapeutics's Accounts Payable for the quarter that ended in Dec. 2025 was €2.28 Mil.

Valerio Therapeutics's quarterly Accounts Payable declined from Dec. 2024 (€5.25 Mil) to Jun. 2025 (€4.09 Mil) and declined from Jun. 2025 (€4.09 Mil) to Dec. 2025 (€2.28 Mil).

Valerio Therapeutics's annual Accounts Payable increased from Dec. 2023 (€2.46 Mil) to Dec. 2024 (€5.25 Mil) but then declined from Dec. 2024 (€5.25 Mil) to Dec. 2025 (€2.28 Mil).

Valerio Therapeutics Accounts Payable Related Terms

Valerio Therapeutics Accounts Payable Historical Data

* Premium members only.

The historical data trend for Valerio Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valerio Therapeutics Accounts Payable Chart

Valerio Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.83 3.45 2.46 5.25 2.28

Valerio Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.46 3.62 5.25 4.09 2.28
XPAR:ALVIO
28GF Score
Valerio Therapeutics XPAR:ALVIO
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valerio Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €2.28 Mil mean?
Valerio Therapeutics (XPAR:ALVIO) has a Accounts Payable of €2.28 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Valerio Therapeutics and its competitors.
Is Valerio Therapeutics' Accounts Payable too high?
Valerio Therapeutics' current Accounts Payable is €2.28 Mil. Overall, Valerio Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Accounts Payable compare to VRTX and REGN?
Valerio Therapeutics' Accounts Payable of €2.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Valerio Therapeutics and its competitors. Valerio Therapeutics's current Accounts Payable is €2.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.61 — trading 771.4% above its estimated fair value. The current Accounts Payable is €2.28 Mil. Valerio Therapeutics' overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Accounts Payable is €2.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?

Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued. The current stock price of €0.61 is trading 771.4% above its estimated GF Value™ of €0.07. GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.

Key valuation signals for XPAR:ALVIO:

  • Accounts Payable: €2.28 Mil
  • GF Value™: €0.07 vs. price of €0.61 (771.4% above fair value)
  • GF Score™: 28/100 with 9 warning signs

No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Valerio Therapeutics Business Description

Other Exchanges 0NWK:UKC4X:Germany
Address 49, Boulevard du General, Martial Valin, Paris, FRA, 75015
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
28GF Score

Get the complete analysis for XPAR:ALVIO

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price
€0.07
GF Value